Loading...
Cadila Pharmaceuticals Limited — Enalapril Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #10 for Enalapril · $1.1M export value · DGFT Verified
Cadila Pharmaceuticals Limited is the #10 Indian exporter of Enalapril with $1.1M in export value and 108 verified shipments. Cadila Pharmaceuticals Limited holds a 0.5% market share in Enalapril exports across 15 countries. The company exports 15 pharmaceutical products worth $20.2M across 11 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| SRI LANKA | $364.1K | 24 | 32.0% |
| SOUTH AFRICA | $330.3K | 13 | 29.0% |
| ZIMBABWE | $155.8K | 9 | 13.7% |
| THAILAND | $69.0K | 12 | 6.1% |
| FRANCE | $59.3K | 6 | 5.2% |
| JAMAICA | $43.8K | 8 | 3.9% |
| TANZANIA | $40.5K | 10 | 3.6% |
| BELGIUM | $22.0K | 6 | 1.9% |
| KENYA | $14.8K | 10 | 1.3% |
| NETHERLANDS | $12.9K | 2 | 1.1% |
Cadila Pharmaceuticals Limited exports Enalapril to 17 countries. The largest destination is SRI LANKA accounting for 32.0% of Cadila Pharmaceuticals Limited's Enalapril shipments, followed by SOUTH AFRICA (29.0%) and ZIMBABWE (13.7%). These destinations reflect Cadila Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| PHARMA-Q | SOUTH AFRICA | $313.1K | 10 |
| SUNSHINE HEALTHCARE LANKA LIMITED | SRI LANKA | $190.5K | 16 |
| SUNSHINE HEALTHCARE LANKA LIMITED. | SRI LANKA | $115.2K | 5 |
| SEASONS PHARMACEUTICALS | ZIMBABWE | $103.5K | 4 |
| MEDICINS SANS FRONTIERES LOGISTIQUE | FRANCE | $53.1K | 5 |
| STATE PHARMACEUTICALS CORPORATION | SRI LANKA |
India exported $32.4M worth of Enalapril through 3,403 shipments from 261 suppliers to 115 countries, serving 583 buyers globally. Cadila Pharmaceuticals Limited contributes $1.1M to this total, accounting for 0.5% of India's Enalapril exports. Cadila Pharmaceuticals Limited ships Enalapril to 17 countries through 36 buyers.
Cadila Pharmaceuticals Limited's average Enalapril shipment value is $10.5K per consignment, based on 108 shipments totaling $1.1M. The largest destination is SRI LANKA (32.0% of Cadila Pharmaceuticals Limited's Enalapril exports).
Cadila Pharmaceuticals Limited ranks #10 among 261 Indian Enalapril exporters with a 0.5% market share. The top 3 exporters are IPCA LABORATORIES LIMITED ($6.2M), J B CHEMICALS AND PHARMACEUTICALS LIMITED ($4.8M), MYLAN LABORATORIES LIMITED ($4.5M). Cadila Pharmaceuticals Limited processed 108 shipments to 15 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| ENVAS 10 2 X 14 TABLETS (R/M : ENALAPRIL | $313.1K | 10 |
| ENVAS 10MG TABLET RAW MATERIAL ENALAPRIL | $75.2K | 3 |
| ENVAS 5 TABLETS (RAW MATERIAL: ENALAPRIL | $51.4K | 2 |
| PHARMA PRODUCT:ENALAPRIL TABLETS 5 MG(SP | $50.0K | 1 |
| PHA DRG & MED ENVAS 5 TABLETS(EACH TABLET CONTAINING ENALAPRIL MALEATE USP 5 MG) QTY. 100T/PAC | $50.0K | 1 |
| PHA DRG & MED ENVAS 10 TABLETS CONT. ENALAPRIL MALEATE TABLET U.S.P. 10 MG QTY.100T/PAC | $41.4K | 2 |
| PHA DRG & MED ENVAS 5 TABLETS CONT. ENALAPRIL MALEATE TABLETS U.S.P. 5 MG QTY. 100T/PACTBS | $35.8K | 3 |
| PHA DRG & MED ENVAS 5 TABLETS CONT. ENALAPRIL MALEATE TABLETS U.S.P. 5 MG QTY.100T/PAC | $35.5K |
What Cadila Pharmaceuticals Limited must comply with to export Enalapril to its top destination countries
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #10 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 8 | MICRO LABS LIMITED | $1.3M | 31 | 4 | $41.0K |
| 9 | EMIL PHARMACEUTICAL INDUSTRIES PVT LTD | $1.2M | 46 | 2 | $27.0K |
| 10 | CADILA PHARMACEUTICALS LIMITED ★ | $1.1M | 108 | 15 | $10.5K |
| 11 | INTAS PHARMACEUTICALS LIMITED | $1.1M |
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 474 | 13.9% |
| DELHI AIR CARGO ACC (INDEL4) | 340 | 10.0% |
| SAHAR AIR | 254 | 7.5% |
| JNPT/ NHAVA SHEVA SEA | 229 | 6.7% |
| SAHAR AIR CARGO ACC (INBOM4) | 222 | 6.5% |
| JNPT | 213 | 6.3% |
| DELHI AIR | 210 | 6.2% |
| MUNDRA SEA (INMUN1) | 124 | 3.6% |
Cadila Pharmaceuticals Limited also exports these cardiovascular products. Each links to the detailed product page.
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Cadila Pharmaceuticals. The ongoing Israel-Iran tensions have led to disruptions in the Red Sea shipping routes, causing major carriers to suspend or reroute transits. This has resulted in extended transit times by 10–20 days and increased freight rates by 40–50% on key India–Europe routes, impacting the timely delivery of pharmaceuticals. (livemint.com)
Conversely, the U.S.-China trade tensions have prompted the United States to diversify its pharmaceutical supply chain, creating opportunities for Indian exporters. However, the U.S. has also implemented tariffs on Active Pharmaceutical Ingredients (APIs), leading to a reshoring of manufacturing and affecting Indian firms. In response, some Indian companies have invested in U.S. facilities to circumvent these tariffs. (odrindia.in)
In the European Union, compliance with the Falsified Medicines Directive (FMD) has become imperative. Indian exporters must ensure stringent adherence to these regulations to maintain market access, necessitating investments in serialization and traceability systems.
Compliance with international regulatory standards is crucial for Indian pharmaceutical exporters. The U.S. Food and Drug Administration (FDA) has previously issued warnings to Cadila Pharmaceuticals regarding deviations from standard manufacturing practices. (business-standard.com) To address such concerns, the company has invested in enhancing its quality control systems and manufacturing processes. Additionally, Cadila has engaged in legal proceedings concerning biosimilar approvals, highlighting the complexities of regulatory compliance in the biosimilars market. (legaleraonline.com)
Cadila Pharmaceuticals Limited exports 15 products worth $20.2M. Beyond Enalapril, top products include Mebendazole, Verapamil, Folic, Domperidone, Ethambutol. View the complete Cadila Pharmaceuticals Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Enalapril — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cadila Pharmaceuticals Limited's Enalapril exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cadila Pharmaceuticals Limited
Full Company Profile →
15 products · $20.2M total trade · 11 categories
| $53.0K |
| 2 |
| PHARMALAND 1982 CO LTD | THAILAND | $27.7K | 2 |
| ZORWAY INTERNATIONAL PVT LTD | ZIMBABWE | $27.0K | 3 |
| NEW VISION DISTRIBUTORS LTD | JAMAICA | $25.9K | 4 |
| SURYA PHARMA LIMITED | TANZANIA | $25.7K | 9 |
Cadila Pharmaceuticals Limited supplies Enalapril to 36 buyers globally. The largest buyer is PHARMA-Q (SOUTH AFRICA), followed by SUNSHINE HEALTHCARE LANKA LIMITED (SRI LANKA) and SUNSHINE HEALTHCARE LANKA LIMITED. (SRI LANKA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| 1 |
| ENVAS 5 TABLETS (RM : ENALAPRIL MALEATE | $30.1K | 2 |
| PHARMACEUTICAL PRODUCT ENVAS 10MG TABLETRAW MATERIAL ENALAPRIL MALEATE USP BATCH B3735007C B373E5008 | $28.4K | 1 |
Cadila Pharmaceuticals Limited exports 80 distinct Enalapril formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ENVAS 10 2 X 14 TABLETS (R/M : ENALAPRIL with 10 shipments worth $313.1K.
| 442 |
| 12 |
| $2.5K |
| 13 | MEDOPHARM | $1.0M | 84 | 12 | $12.4K |
Cadila Pharmaceuticals Limited ranks #10 among 261 Indian Enalapril exporters. Average shipment value of $10.5K compared to the market average of $124.2K. The closest competitors by value are MICRO LABS LIMITED and EMIL PHARMACEUTICAL INDUSTRIES PVT LTD.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 115+ countries, 583+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Cadila Pharmaceuticals Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Enalapril. For current shipment-level data, contact TransData Nexus.